Akeso's Gumokimab Secures Approval for Ankylosing Spondylitis in China

Akeso's Breakthrough in Ankylosing Spondylitis Treatment



In a significant advancement in the treatment of autoimmune diseases, Akeso, Inc. has received approval from the National Medical Products Administration (NMPA) in China for its IL-17A monoclonal antibody, Gumokimab. This approval specifically indicates the drug's use in managing active ankylosing spondylitis (AS), a chronic inflammatory condition that can severely affect patients' quality of life.

Approval Details


On November 16, 2026, Akeso announced that the regulatory body had given the green light for a supplemental New Drug Application (sNDA) for Gumokimab, marking the second approved indication for this innovative therapy. Previously, in June 2026, the drug was approved for the treatment of moderate-to-severe plaque psoriasis, showcasing its versatility in addressing different autoimmune conditions.

The recent approval for ankylosing spondylitis stems from the successful outcomes of the Phase 3 registration trial known as AK111-303. This study demonstrated that Gumokimab met all key efficacy endpoints, providing fast and significant relief from AS symptoms. It notably improved patients' physical functionality, disease activity, and overall quality of life.

Understanding Ankylosing Spondylitis


Ankylosing spondylitis is characterized by inflammation mainly in the spine and the sacroiliac joints, potentially leading to significant structural damage and reduced mobility over time. The disease is rooted in the dysfunction of immune responses where pro-inflammatory cytokines, like IL-17A, play a crucial role in the inflammatory cascade associated with the disease. By targeting IL-17A, Gumokimab effectively interrupts this process, providing a robust therapeutic approach.

Scientific Backing and Clinical Insights


Professor Rong Mu from Peking University Third Hospital, who served as the principal investigator for the AK111-303 study, explained that managing ankylosing spondylitis presents ongoing challenges. Current treatment methods don’t always provide satisfactory long-term control or comprehensive response for patients. In this regard, Gumokimab has exhibited the potential to alleviate symptoms such as pain and stiffness and improve overall physical function and life quality.

He emphasized the importance of having a reliable treatment option that can achieve profound disease control and delay the progression of structural damage associated with ankylosing spondylitis.

Akeso's Vision for the Future


Dr. Michelle Xia, Akeso’s Founder and CEO, expressed gratitude towards all those who participated in the clinical trials for Gumokimab. She noted that while there are substantial unmet needs in the realm of autoimmune diseases, Akeso remains dedicated to developing innovative solutions. The company is currently advancing multiple therapies in its pipeline, including ebdarokimab (IL-12/IL-23) and manfidokimab (IL-4Rα), both of which aim to broaden treatment options for patients worldwide.

Conclusion


The NMPA approval of Gumokimab represents a crucial milestone for Akeso and a promising new chapter for patients with ankylosing spondylitis in China. By fostering innovative treatments for autoimmune diseases, Akeso is on the pathway to enhancing patient care and quality of life. As the company continues to develop new therapies, the global landscape for effective autoimmune disease management is set to evolve, offering hope and solutions to many.

With Gumokimab's availability, patients in China now have an additional powerful tool in managing their condition, potentially leading to better clinical outcomes and improved daily living.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.